LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Conference Call Details
Date: | Wednesday, February 19, 2025 |
Time: | 5:00 p.m. U.S. EST |
Webcast: |
A replay of the conference call will be available on the investor relations website.
To participate in the live Q&A session, please register using this link to receive an email confirming your registration.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
Investor Contact:
Garen Sarafian
This email address is being protected from spambots. You need JavaScript enabled to view it.
(877) 281-6642 (toll-free)
Media Contact:
Katie Savastano
This email address is being protected from spambots. You need JavaScript enabled to view it.
(908) 541-3785
| Last Trade: | US$5.10 |
| Daily Change: | 0.60 13.33 |
| Daily Volume: | 8,623,981 |
| Market Cap: | US$1.880B |
February 19, 2025 October 30, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
